News
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023.
The fourth-quarter 2023
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year
EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment
EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board
New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged
EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market
Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)
EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
Nicolas Poirier, Chief Executive Officer
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle